Zai Lab (NASDAQ:ZLAB) Insider Sells $202,064.90 in Stock
by Amy Steele · The Cerbat GemZai Lab Limited Unsponsored ADR (NASDAQ:ZLAB – Get Free Report) insider Rafael Amado sold 9,910 shares of the company’s stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $20.39, for a total value of $202,064.90. Following the completion of the transaction, the insider owned 59,761 shares in the company, valued at $1,218,526.79. This represents a 14.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Rafael Amado also recently made the following trade(s):
- On Friday, March 13th, Rafael Amado sold 2,957 shares of Zai Lab stock. The shares were sold at an average price of $18.63, for a total value of $55,088.91.
Zai Lab Stock Performance
Shares of NASDAQ ZLAB remained flat at $20.41 during midday trading on Friday. The stock had a trading volume of 707,427 shares, compared to its average volume of 746,471. Zai Lab Limited Unsponsored ADR has a 52 week low of $15.96 and a 52 week high of $44.34. The stock has a market capitalization of $2.30 billion, a P/E ratio of -12.68 and a beta of 0.86. The firm has a 50-day moving average price of $18.63 and a two-hundred day moving average price of $21.91.
Zai Lab (NASDAQ:ZLAB – Get Free Report) last posted its quarterly earnings data on Saturday, February 14th. The company reported ($0.50) earnings per share for the quarter. The company had revenue of $127.60 million during the quarter. Zai Lab had a negative return on equity of 22.81% and a negative net margin of 38.15%. On average, equities research analysts forecast that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several analysts have recently weighed in on ZLAB shares. Zacks Research cut shares of Zai Lab from a “hold” rating to a “strong sell” rating in a research report on Friday, January 23rd. JPMorgan Chase & Co. reduced their target price on Zai Lab from $39.00 to $32.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 18th. Cantor Fitzgerald lowered their price target on Zai Lab from $55.00 to $37.00 and set an “overweight” rating on the stock in a research report on Friday, February 27th. Jefferies Financial Group raised Zai Lab to a “strong-buy” rating in a research note on Monday, January 19th. Finally, UBS Group began coverage on Zai Lab in a report on Wednesday, January 7th. They issued a “buy” rating and a $35.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $50.00.
Check Out Our Latest Report on ZLAB
Hedge Funds Weigh In On Zai Lab
An institutional investor recently bought a new position in Zai Lab stock. SG Americas Securities LLC purchased a new position in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB – Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 9,754 shares of the company’s stock, valued at approximately $331,000. 41.65% of the stock is owned by hedge funds and other institutional investors.
Zai Lab Company Profile
Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.
The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.